2022
Gene Sequencing Identifies Perturbation in Nitric Oxide Signaling as a Nonlipid Molecular Subtype of Coronary Artery Disease
Khera AV, Wang M, Chaffin M, Emdin CA, Samani NJ, Schunkert H, Watkins H, McPherson R, Erdmann J, Elosua R, Boerwinkle E, Ardissino D, Butterworth A, Di Angelantonio E, Naheed A, Danesh J, Chowdhury R, Krumholz H, Sheu W, Rich S, Rotter J, Chen Y, Gabriel S, Lander E, Saleheen D, Kathiresan S. Gene Sequencing Identifies Perturbation in Nitric Oxide Signaling as a Nonlipid Molecular Subtype of Coronary Artery Disease. Circulation Genomic And Precision Medicine 2022, 15: e003598. PMID: 36215124, PMCID: PMC9771961, DOI: 10.1161/circgen.121.003598.Peer-Reviewed Original ResearchConceptsMolecular subtypesCAD riskHigher systolic blood pressureCoronary artery disease patientsEndothelial nitric oxide synthase geneDamaging missense variantsRisk of CADSystolic blood pressureCoronary artery diseaseRisk of hypertensionNitric oxide synthase geneMissense variantsNitric oxide synthesisRare variantsOxide synthase geneDiscrete molecular subtypesNitric Oxide SignalingLow density lipoprotein receptor geneArtery diseaseBlood pressureEndothelial functionVascular toneDisease patientsCAD casesCholesterol concentrations
2010
Optimizing statin treatment for primary prevention of coronary artery disease.
Hayward RA, Krumholz HM, Zulman DM, Timbie JW, Vijan S. Optimizing statin treatment for primary prevention of coronary artery disease. Annals Of Internal Medicine 2010, 152: 69-77. PMID: 20083825, DOI: 10.7326/0003-4819-152-2-201001190-00004.Peer-Reviewed Original ResearchMeSH KeywordsAdultAgedCholesterol, LDLClinical Trials as TopicComputer SimulationCoronary Artery DiseaseDrug Administration ScheduleFemaleGuideline AdherenceHumansHydroxymethylglutaryl-CoA Reductase InhibitorsMaleMiddle AgedPrimary PreventionQuality-Adjusted Life YearsRisk FactorsSensitivity and SpecificityTreatment OutcomeConceptsHigh-dose statinsQuality Enhancement Research InitiativeStatin therapyMore QALYsNational Cholesterol Education Program III guidelinesTreatment approachesCoronary artery disease preventionVeterans Affairs Health Services ResearchDoses of statinsCoronary artery diseaseRisk factor dataAvailable clinical dataYears of treatmentTarget approachBase-case analysisHealth services researchPersons 75 yearsStatin doseStatin trialsCAD eventsStatin treatmentArtery diseaseCAD riskPrimary preventionMyocardial infarction